In a second randomized controlled trial, 39 patients with moderately elevated fasting blood glucose levels were randomized to receive two RYR capsules (220 mg total) a day or placebos, for 12 weeks. Patients’ blood samples were collected at four-week intervals during the trial, and four weeks afterwards (16 weeks after trial start). In the RYR group, the mean fasting blood glucose decreased by 9% after six weeks, returning to baseline four weeks after the end of the trial. Similarly, plasma LDL-C decreased by 8% after six weeks but had returned to baseline at 12 weeks. There were no significant changes in blood glucose or LDL-C in the placebo patients.
Wang YR, Liu SF, Shen YC, et al. A randomized, double-blind clinical study to determine the effect of ANKASCIN 568 plus on blood glucose regulation. J Food Drug Anal. 2017;25(2):409-416. doi:10.1016/j.jfda.2016.06.011..